interferoninduc
transmembran
ifitm
protein
known
inhibit
replic
pathogen
virus
influenza
dengu
filovirus
marburg
viru
ebola
viru
coronavirus
eg
sever
acut
respiratori
syndrom
sar
ifitm
protein
interfer
viral
replic
preced
fusion
viral
cellular
membran
detail
antivir
mechan
ifitm
remain
unknown
recent
year
crucial
role
protein
mostli
studi
control
influenza
viru
infect
everitt
et
al
use
knockout
mous
model
show
mice
lack
gene
display
fulmin
viral
pneumonia
infect
lowpathogen
influenza
viru
likewis
invitro
studi
increas
viral
replic
observ
absenc
reintroduc
restrict
replic
influenza
viru
human
rare
singlenucleotid
polymorph
snp
allel
homozyg
alter
outcom
influenza
viru
infect
identifi
allel
frequenc
snp
much
higher
han
chines
popul
minor
allel
frequenc
maf
compar
northern
european
popul
maf
previous
studi
associ
allel
sever
influenza
viru
infect
chines
patient
found
chines
patient
sever
pandem
influenza
viru
infect
carri
cc
genotyp
compar
mild
infect
two
studi
shown
restrict
effect
progress
acut
infect
howev
role
allel
acut
infect
explor
jia
et
al
show
inhibit
virus
enter
cell
via
differ
rout
presenc
late
endosom
block
cytosol
access
phdepend
virus
influenza
howev
phindepend
virus
appear
restrict
viral
cell
entri
cell
peripheri
earli
endosom
furthermor
inhibit
replic
vitro
reduc
express
protein
gag
vif
nef
rais
question
minor
allel
caucasian
effect
acut
infect
influenza
viru
especi
pertin
grow
concern
spread
hiv
china
particular
among
msm
address
question
screen
individu
hiv
primari
open
cohort
primo
beij
china
compar
clinic
outcom
ttgenotyp
carrier
everi
month
volunt
primo
cohort
beij
check
earli
sign
acut
infect
describ
previous
addit
plasma
collect
test
antibodi
rna
level
amongst
individu
diagnos
acut
infect
anoth
volunt
enrol
control
group
everi
month
thereaft
detect
seronvers
whole
blood
specimen
collect
follow
blood
collect
plasma
peripher
blood
mononuclear
cell
pbmc
separ
studi
studi
approv
institut
review
board
beij
hospit
written
inform
consent
obtain
patient
acut
infect
defin
posit
rna
test
negativeindetermin
elisa
western
blot
test
rapid
clinic
progress
defin
time
treatment
initi
time
estim
lymphocyt
count
lower
within
year
seroconvers
show
signific
tcell
declin
defin
nonprogressor
initi
peak
viremia
level
defin
accord
dynam
viremia
acut
patient
initi
viral
load
indic
viral
load
detect
fiebig
stage
peak
viremia
level
refer
highest
viral
load
detect
acut
infect
setpoint
definit
establish
criteria
describ
fellay
et
al
strictli
follow
defin
threephas
evolut
viremia
calcul
averag
viral
load
setpoint
tabl
detect
specif
antibodi
standard
hiv
type
elisa
abbott
abbott
park
illinoi
usa
western
blot
analysi
genelab
redwood
citi
california
usa
kit
use
copi
plasma
rna
quantifi
serum
roch
amplicor
kit
roch
molecular
diagnost
indianapoli
indiana
usa
absolut
count
cell
cell
measur
use
tritest
threecolor
reagent
bd
compani
franklin
lake
new
jersey
usa
multiset
softwar
facscalibur
flow
cytometri
system
determin
subtyp
gag
gene
infect
individu
amplifi
sequenc
beij
institut
genom
bgi
shenzhen
china
nucleotid
sequenc
analyz
use
recombin
identif
program
rip
softwar
alamo
hiv
sequenc
databas
genom
dna
extract
pbmc
use
puregen
dna
isol
kit
gentra
system
detroit
michigan
usa
region
encompass
human
sequenc
amplifi
sequenc
analyz
describ
previous
statist
analysi
genet
data
perform
use
chisquar
test
associ
test
differ
genet
model
fisher
exact
test
use
sinc
chisquar
approxim
might
hold
small
sampl
size
student
test
use
compar
valu
ctcc
group
case
data
normal
distribut
evalu
test
nonparametr
test
test
use
data
normal
distribut
surviv
analysi
logrank
test
employ
identifi
differ
progress
cell
patient
tt
ctcc
genotyp
statist
test
differ
consid
signific
p
valu
less
analys
perform
graphpad
prism
v
graphpad
softwar
lajolla
california
usa
infect
individu
identifi
rapid
progressor
describ
method
materi
section
patient
signific
declin
group
nonprogressor
signific
differ
tcell
count
rapid
progressor
nonprogressor
observ
seroconvers
vs
p
month
vs
p
month
vs
p
month
vs
p
seroconvers
addit
progressor
show
significantli
higher
viral
load
setpoint
compar
nonprogressor
p
tabl
three
hundr
base
pair
locu
encompass
snp
sequenc
acut
patient
control
group
among
rapid
progressor
carri
ccct
genotyp
higher
frequenc
individu
p
wherea
genotyp
frequenc
nonprogressor
significantli
differ
group
p
associ
progress
infect
test
genet
model
describ
previous
significantli
higher
frequenc
ccct
genotyp
found
rapid
progressor
compar
nonprogressor
p
particular
domin
model
carrier
c
allel
show
threefold
increas
risk
rapid
infect
progress
compar
carrier
allel
p
odd
ratio
confid
interv
ci
peak
viremia
viral
load
significantli
higher
ccct
carrier
compar
tt
genotyp
carrier
vs
p
fig
howev
signific
differ
viral
load
level
ccct
tt
genotyp
carrier
initi
infect
viral
set
point
heterozygot
homozygot
c
allel
show
significantli
lower
tcell
count
homozygot
allel
seroconvers
time
point
vs
p
third
vs
p
sixth
vs
p
month
vs
p
acut
infect
fig
identifi
whether
differ
diseas
progress
individu
tcell
count
ccct
genotyp
carri
versu
tt
genotyp
carrier
logrank
test
perform
result
test
verifi
ccct
genotyp
carrier
like
becom
rapid
progressor
p
fig
four
differ
subtyp
identifi
among
acut
patient
cohort
distribut
describ
subtyp
b
subtyp
bc
subtyp
c
subtyp
ae
find
differ
distribut
subtyp
rapid
nonprogressor
data
shown
howev
higher
percentag
rapid
progressor
ccct
genotyp
carrier
regardless
infect
subtyp
data
shown
current
studi
show
genet
variant
associ
rapid
progress
infect
significantli
higher
frequenc
ccct
genotyp
observ
rapid
progressor
compar
nonprogressor
found
ccct
genotyp
carrier
higher
peak
viremia
level
lower
tcell
count
strikingli
cctc
genotyp
significantli
higher
chanc
tcell
count
fall
less
first
year
infect
howev
genet
associ
acquisit
infect
sinc
signific
differ
distribut
genotyp
acut
patient
control
current
result
could
partli
explain
rapid
progress
infect
observ
beij
primo
cohort
chines
cohort
compar
concert
action
seroconvers
aid
death
europ
cascad
cohort
primo
studi
tcell
declin
viral
load
increas
faster
chines
msm
cohort
ctcc
genotyp
carrier
compar
cascad
popul
ctcc
genotyp
carrier
howev
mani
factor
host
viru
like
contribut
differ
still
clear
snp
affect
express
predict
mutat
may
result
express
truncat
lack
first
amino
acid
nterminu
previou
mechanist
studi
base
assumpt
conclus
rather
controversi
howev
exist
truncat
protein
cell
snp
allel
yet
shown
cell
transfect
synthet
truncat
version
lack
first
amino
acid
reloc
late
endosom
cell
peripheri
reloc
cell
surfac
might
affect
viral
entri
moreov
tartour
et
al
suggest
ifitm
protein
incorpor
virion
particl
impair
infect
find
could
partli
explain
result
nonetheless
studi
requir
answer
follow
question
presenc
snp
allel
result
express
truncat
protein
local
differ
full
length
simpli
affect
level
express
current
investig
answer
question
conclus
data
clearli
show
ccct
genotyp
associ
rapid
progress
acut
infect
regardless
subtyp
howev
associ
diseas
acquisit
conflict
interest
